Headlines about OncoGenex Pharmaceuticals (NASDAQ:ACHV) have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. OncoGenex Pharmaceuticals earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.9068446822637 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Separately, ValuEngine upgraded OncoGenex Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th.
OncoGenex Pharmaceuticals (ACHV) opened at $1.18 on Friday. OncoGenex Pharmaceuticals has a 1 year low of $1.17 and a 1 year high of $10.23.
About OncoGenex Pharmaceuticals
Achieve Life Sciences, Inc, formerly OncoGenex Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States.
Receive News & Ratings for OncoGenex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoGenex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.